www.ias2015.org lessons learned from transient remission cases: clues to biomarkers of hiv rebound...
TRANSCRIPT
www.ias2015.org
Lessons Learned from Transient Remission Cases:
Clues to Biomarkers of HIV Rebound
Katherine Luzuriaga, MDUniversity of Massachusetts Medical School
Worcester, MA USA
www.ias2015.org
• New pediatric infections (MTCT) cut by 50% between 2001 and 2012: 900,000 new infections prevented since 2009
• 3.2 million children < 15 yrs living with HIV
• 1.5 million HIV-1+ women give birth each year; only ~68% receive ART for PMTCT
• 240, 000 children acquire HIV-1: one new infection every 2 minutes
UNAIDS, 2014
Global Eradication of Pediatric HIV-1 Infection
www.ias2015.org
Rationale for Early cART
• Rapid tempo of disease progression in HIV infected infants • Median viral loads > 105 copies/ml over first 2 years of life• High rates of viral production• Less robust adaptive HIV-specific immunity
• Ready identification of infants at risk and ability to make early nucleic acid-based rapid diagnosis
• Early cART reduces HIV-related morbidity and mortality (Violari et al, NEJM, 2008)• Early HIV diagnosis and cART are globally recommended as standard
of care
www.ias2015.org
Early cART restricts the latent reservoir
Persaud et al. AIDS, 2012
Restricted latent reservoir if treated < 6 wk (red circles) vs. > 6 wk (blue circles)
Reservoir decays over the first 2 yrs in early-treated infants (half-life 11 months [95% CI: 6 to 30 months]
Remains detectable in most (60%) at two years of age
www.ias2015.org
Lower PBMC DNA Levels In Children With Younger Age at Virologic Control
Persaud et al, JAMA Pediatr, 2014
Median 4.2 19 71
2-LTR DNA circles detectable in 20% of youth:
Proviral DNA copy number higher in those with detectable (median = 191) than in those with undetectable (median = 23) 2-LTR circles
www.ias2015.org
Clearance of HIV-specific Antibodies is a Hallmark of Early Effective cART in Infants
EIA negative at 15 months:
A. Durable HIV RNA suppression to < 400:
11 (73%) of 15 infants
B. Early tx, incomplete /transient suppression:
None (0%) of 5
C. HIV-uninfected infants born to HIV-infected women:
5 (100%) of 5
D. HIV- infected infants first treated > 12 mo:
None (0%) of 4
Luzuriaga et al, J Virol, 2000
www.ias2015.org
Low Proviral DNA Loads in Children with HIV-1 Negative or Indeterminate Wb
Persaud et al, JAMA Pediatr, 2014.
www.ias2015.org
Early and Very Early Therapy Restrict the Size and Modify the Persistence of HIV-1 Reservoirs
Luzuriaga, CROI, 2014; Persaud, CROI, 2015; Luzuriaga, JID, 2014; Persaud, JAMA Peds, 2014; Ananworanich, AIDS, 2014; van Zyl, JID, 2015; Bitnun, CID, 2014
Contribution to the proviral reservoir: TTM > TCM, EM
www.ias2015.org
HIV Remission Following Very Early cART
AZT/3TC/NVP
AZT/3TC/LPV/r
AZT/3TC/EFV
+RAL
ARV administered 31 hours - 18 months
Remission 28 months off cART
• No detectable HIV-1 in routine or scRNA assay • No replication-competent virus recovered• No detectable HIV-1 specific antibodies or CD4/CD8+ T cells• Absence of host factors associated with elite control
Viral Rebound at age 46 months
Persaud et al, NEJM, 2013; Luzuriaga, NEJM, 2015
SC RNA: 9 copies/ml
www.ias2015.org
HIV-1 rebound despite limited proviral and latent reservoirs
Bitnun, CID, 2014; Giacomet, PIDJ, 2014; Persaud, NEJM, 2014; Luzuriaga, NEJM, 2015; Vigano, J Peds, 2006
www.ias2015.org
Summary: Early/Very Early cART Alters HIV-1 Persistence in Children
• Limits proviral and replication competent reservoirs • Size correlated with the rapidity of control of
HIV replication • Decay rapidly over first year of therapy• Slower decay with prolonged suppression of
HIV replication • Decay in HIV proviral reservoirs over time in
absence of HIV-specific immune responses suggests that early cART limits infection of long-lived cells
• Contribution to the proviral reservoir: TTM > TCM, EM
www.ias2015.org
Markers for low-level proviral and latent reservoirs
• Plasma RNA below detection limits of single copy assays
• Lack of detectable 2 LTR DNA circles
• Absence of T cell activation • Lack of HIV-specific antibodies,
and CD4 and CD8+ T cell responses
Luzuriaga et al, J Virol, 2000;
Persaud et al, JAMA Peds, 2014; Ananworanich et al, AIDS, 2014
www.ias2015.org
Adults: 5-15% treated during PHI• On cART 12-192 mo (median 36 mo)• Remission off cART: 48-115 mo (median 89 mo)• Low level T cell activation and HIV-specific T cell
responses• Low circulating HIV-1 DNA levels (median 52 c/106
PBMC), with progressive decline over time in some
Pediatric case• Infected despite infant ARV prophylaxis• Received cART ~3 mo – 6 years• Plasma HIV-1 RNA < 50 for 12 years, except for
blips at 1, 2, 11, and 14 years; now < 4-9 c/ml• HIV-1 DNA 125-136 copies per million PBMC
Pathways to Remission: Post-Treatment Controllers
Saez-Cirion, PLoS Pathogens, 2013Saez-Cirion, IAS, 2015
www.ias2015.org
IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected infants to achieve HIV remission: A proof of concept study
IMPAACT P1107: Cord Blood Transplantation with CCR5Δ32 Donor Cells in HIV-Infected Subjects who Require Bone Marrow Transplantation for any Indication and its Observed Effects on HIV-1 Persistence
Current Protocols
www.ias2015.org
Early/Very cART and HIV Persistence in Children
HIV positive infants and children with persistent suppression of HIV on cART are excellent candidates for additional strategies aimed at remission, particularly therapeutic vaccines:
• Normal immune responses• Absent HIV-specific immunity • Limited viral diversity
www.ias2015.org
Acknowledgements
Children and Families
Hannah Gay and Deborah Persaud
Persaud Lab: Carrie Ziemniak, Ya Hui Chen
Luzuriaga Lab: Margaret McManus, Linda Lambrecht, Joyce Pepe, Robin Brody, Keri Sanborn, Jim Coderre, Mohan Somasundaran
Collaborators: Matthew Strain, Danielle Murray, Douglas Richman, Tae-Wook Chun
Manuel Garber, Barbara Tabak Funding: NIAID, NICHD, AmFAR, JHU CFAR, UMMS CFAR, UMass Center for Clinical and Translational Science